vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and FiscalNote Holdings, Inc. (NOTE). Click either name above to swap in a different company.

FiscalNote Holdings, Inc. is the larger business by last-quarter revenue ($22.2M vs $19.6M, roughly 1.1× STANDARD BIOTOOLS INC.). On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -24.7%). FiscalNote Holdings, Inc. produced more free cash flow last quarter ($-1.9M vs $-23.1M). Over the past eight quarters, STANDARD BIOTOOLS INC.'s revenue compounded faster (-12.2% CAGR vs -16.8%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

FiscalNote Holdings, Inc., or commonly FiscalNote, is a publicly traded software, data, and media company headquartered in Washington, D.C. The company was founded by Timothy Hwang, Gerald Yao, and Jonathan Chen in 2013. FiscalNote provides software tools, platforms, data services, and news through the FiscalNote Government Relationship Management (GRM) service, its core product. The company also uses an artificial intelligence platform to analyze proposed U.S. legislation based on key phrase...

LAB vs NOTE — Head-to-Head

Bigger by revenue
NOTE
NOTE
1.1× larger
NOTE
$22.2M
$19.6M
LAB
Growing faster (revenue YoY)
LAB
LAB
+13.2% gap
LAB
-11.5%
-24.7%
NOTE
More free cash flow
NOTE
NOTE
$21.2M more FCF
NOTE
$-1.9M
$-23.1M
LAB
Faster 2-yr revenue CAGR
LAB
LAB
Annualised
LAB
-12.2%
-16.8%
NOTE

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
NOTE
NOTE
Revenue
$19.6M
$22.2M
Net Profit
$-34.7M
Gross Margin
48.5%
Operating Margin
-168.5%
-83.7%
Net Margin
-177.4%
Revenue YoY
-11.5%
-24.7%
Net Profit YoY
-28.8%
EPS (diluted)
$-0.09
$-2.81

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
NOTE
NOTE
Q4 25
$22.2M
Q3 25
$19.6M
$22.4M
Q2 25
$21.8M
$23.3M
Q1 25
$40.8M
$27.5M
Q4 24
$29.5M
Q3 24
$22.1M
$29.4M
Q2 24
$22.5M
$29.2M
Q1 24
$45.5M
$32.1M
Net Profit
LAB
LAB
NOTE
NOTE
Q4 25
Q3 25
$-34.7M
$-24.9M
Q2 25
$-33.5M
$-13.3M
Q1 25
$-26.0M
$-4.3M
Q4 24
Q3 24
$-26.9M
$-14.9M
Q2 24
$-45.7M
$-12.8M
Q1 24
$-32.2M
$50.6M
Gross Margin
LAB
LAB
NOTE
NOTE
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
NOTE
NOTE
Q4 25
-83.7%
Q3 25
-168.5%
-43.4%
Q2 25
-118.1%
-31.9%
Q1 25
-80.8%
-50.0%
Q4 24
-19.4%
Q3 24
-120.9%
-23.1%
Q2 24
-134.5%
-27.2%
Q1 24
-132.2%
-35.6%
Net Margin
LAB
LAB
NOTE
NOTE
Q4 25
Q3 25
-177.4%
-110.8%
Q2 25
-153.7%
-57.0%
Q1 25
-63.8%
-15.4%
Q4 24
Q3 24
-122.0%
-50.7%
Q2 24
-203.3%
-43.6%
Q1 24
-70.6%
157.6%
EPS (diluted)
LAB
LAB
NOTE
NOTE
Q4 25
$-2.81
Q3 25
$-0.09
$-1.73
Q2 25
$-0.09
$-0.08
Q1 25
$-0.07
$-0.03
Q4 24
$1.88
Q3 24
$-0.07
$-1.33
Q2 24
$-0.12
$-0.09
Q1 24
$-0.27
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
NOTE
NOTE
Cash + ST InvestmentsLiquidity on hand
$129.4M
$26.3M
Total DebtLower is stronger
$128.4M
Stockholders' EquityBook value
$399.7M
$62.0M
Total Assets
$539.6M
$255.1M
Debt / EquityLower = less leverage
2.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
NOTE
NOTE
Q4 25
$26.3M
Q3 25
$129.4M
$31.2M
Q2 25
$158.6M
$38.5M
Q1 25
$150.9M
$46.3M
Q4 24
$34.6M
Q3 24
$210.6M
$32.7M
Q2 24
$269.8M
$37.7M
Q1 24
$287.1M
$43.6M
Total Debt
LAB
LAB
NOTE
NOTE
Q4 25
$128.4M
Q3 25
$131.5M
Q2 25
$116.7M
Q1 25
$118.0M
Q4 24
$147.1M
Q3 24
$55.2M
$152.2M
Q2 24
$55.1M
$145.9M
Q1 24
$55.0M
$153.0M
Stockholders' Equity
LAB
LAB
NOTE
NOTE
Q4 25
$62.0M
Q3 25
$399.7M
$75.5M
Q2 25
$424.5M
$95.1M
Q1 25
$454.6M
$98.7M
Q4 24
$97.8M
Q3 24
$489.3M
$98.5M
Q2 24
$510.3M
$106.9M
Q1 24
$577.3M
$106.1M
Total Assets
LAB
LAB
NOTE
NOTE
Q4 25
$255.1M
Q3 25
$539.6M
$273.9M
Q2 25
$557.0M
$288.3M
Q1 25
$579.6M
$299.7M
Q4 24
$326.2M
Q3 24
$681.5M
$337.9M
Q2 24
$708.7M
$346.3M
Q1 24
$777.7M
$357.8M
Debt / Equity
LAB
LAB
NOTE
NOTE
Q4 25
2.07×
Q3 25
1.74×
Q2 25
1.23×
Q1 25
1.20×
Q4 24
1.50×
Q3 24
0.11×
1.54×
Q2 24
0.11×
1.36×
Q1 24
0.10×
1.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
NOTE
NOTE
Operating Cash FlowLast quarter
$-22.2M
$-279.0K
Free Cash FlowOCF − Capex
$-23.1M
$-1.9M
FCF MarginFCF / Revenue
-118.1%
-8.7%
Capex IntensityCapex / Revenue
4.5%
7.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$-18.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
NOTE
NOTE
Q4 25
$-279.0K
Q3 25
$-22.2M
$-8.3M
Q2 25
$-20.7M
$-6.2M
Q1 25
$-30.3M
$3.3M
Q4 24
$-1.3M
Q3 24
$-27.9M
$-3.0M
Q2 24
$-39.0M
$-3.7M
Q1 24
$-62.5M
$2.7M
Free Cash Flow
LAB
LAB
NOTE
NOTE
Q4 25
$-1.9M
Q3 25
$-23.1M
$-10.4M
Q2 25
$-22.6M
$-7.7M
Q1 25
$-35.3M
$1.3M
Q4 24
$-3.4M
Q3 24
$-30.1M
$-5.4M
Q2 24
$-41.0M
$-6.5M
Q1 24
$-63.3M
$1.0M
FCF Margin
LAB
LAB
NOTE
NOTE
Q4 25
-8.7%
Q3 25
-118.1%
-46.2%
Q2 25
-103.6%
-33.0%
Q1 25
-86.6%
4.7%
Q4 24
-11.4%
Q3 24
-136.4%
-18.4%
Q2 24
-182.2%
-22.1%
Q1 24
-138.9%
3.3%
Capex Intensity
LAB
LAB
NOTE
NOTE
Q4 25
7.4%
Q3 25
4.5%
9.3%
Q2 25
8.7%
6.4%
Q1 25
12.4%
7.2%
Q4 24
6.8%
Q3 24
10.2%
8.3%
Q2 24
8.6%
9.4%
Q1 24
1.7%
5.3%
Cash Conversion
LAB
LAB
NOTE
NOTE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

NOTE
NOTE

Subscription$21.2M95%
Advisory Advertising And Other$1.0M5%

Related Comparisons